Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor
- 1 June 2003
- journal article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 9 (6) , 244-250
- https://doi.org/10.1016/s1471-4914(03)00074-1
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Recent advances in angiogenesis, anti-angiogenesis and vascular targetingTrends in Pharmacological Sciences, 2002
- Role of angiogenesis in tumor growth and metastasisSeminars in Oncology, 2002
- Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathyAmerican Journal of Ophthalmology, 2002
- Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration11InternetAdvance publication at ajo.com. May 7, 2002.American Journal of Ophthalmology, 2002
- PEDF: anti-angiogenic guardian of ocular functionTrends in Molecular Medicine, 2002
- Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathyAmerican Journal of Ophthalmology, 2002
- Loss of the Antiangiogenic Pigment Epithelium-Derived Factor in Patients With Angiogenic Eye DiseaseDiabetes, 2001
- Novel mechanism for age‐related macular degeneration: An equilibrium shift between the angiogenesis factors VEGF and PEDFJournal of Cellular Physiology, 2001
- Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachmentAmerican Journal of Ophthalmology, 2001
- Blood Vessel Formation: What Is Its Molecular Basis?Cell, 1996